The proprietary P2 Plasma Enrichment method leverages a novel single-well, single particle-type enrichment method to achieve market-leading performance for unbiased, deep mass spectrometry-based plasma proteomics P2 now offers excellent quantitation and higher throughput for large-cohort biomarker or drug discovery studies, and clinical, epidemiological or population proteomics research P2 Plasma Enrichment is available as a CRO service via Biognosys’ TrueDiscovery® platform, or as an in-house method for high-performance mass spectrometry end-users via licensing With the optional additional combination of TrueDiscovery® unbiased, deep mass spectrometry proteomics workflows with targeted Alamar NULISA affinity-based ultra-high sensitivity proteomics panels, Biognosys now enables the most quantitative and complete access to the human plasma proteome ZURICH, Switzerland and NEWTON, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Biognosys, a leader in next-generation proteomics services, software and kits for life sciences research and drug development, today announced the launch of the novel, proprietary P2 Plasma Enrichment method for single-well, single particle-type enrichment with market leading performance and sensible, superior economics.

专有的P2血浆富集方法利用一种新颖的单孔、单颗粒型富集方法，为基于深度质谱的无偏血浆蛋白质组学P2实现了市场领先的性能，现在为大型队列生物标志物或药物发现研究提供了优异的定量和更高的通量，临床、流行病学或人群蛋白质组学研究P2血浆富集可以通过Biognosys的TrueDiscovery®平台作为CRO服务提供，也可以通过TrueDiscovery®无偏深度质谱蛋白质组学工作流程与基于Alamar NULISA亲和力的超高灵敏度蛋白质组学面板的可选附加组合，作为高性能质谱最终用户的内部方法，Biognosys现在可以实现对2024年5月30日，瑞士苏黎世和马萨诸塞州牛顿的人血浆蛋白质组学（Global NEWSWIRE）——Biognosys，下一代蛋白质组学服务的领导者，用于生命科学研究和药物开发的软件和试剂盒今天宣布推出新型专有P2血浆富集方法，用于单孔单颗粒型富集，具有市场领先的性能和合理的优越经济性。

P2-based plasma proteomics can be used for human or for animal-model proteomics studies and clinical research. This novel P2 plasma proteomics method achieves a proteome coverage of 7,000 proteins in a previously published five-cancer plasma sample set, demonstrating highest reproducibility, unprecedented enrichment of low abundant proteins, and unparalleled throughput on Bruker timsTOF® HT mass spectrometers.

基于P2的血浆蛋白质组学可用于人类或动物模型蛋白质组学研究和临床研究。这种新颖的P2血浆蛋白质组学方法在先前发布的五种癌症血浆样品集中实现了7000种蛋白质的蛋白质组覆盖率，在Bruker timsTOF®HT质谱仪上显示出最高的重现性，前所未有的低丰度蛋白质富集和无与伦比的通量。

The technical features and performance data will be presented at the American Society of Mass Spectrometry (ASMS) Annual Conferen.

技术特征和性能数据将在美国质谱学会（ASMS）年度会议上介绍。